3 Einträge gefunden

1. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV

   1. Hehlmann, Rüdiger
   2. Müller, Martin C
   3. Lauseker, Michael
   4. Hanfstein, Benjamin
   5. Fabarius, Alice
   6. Schreiber, Annette
   7. Proetel, Ulrike

   2014 - Forschungsinformationssystem des UKE
2. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

   1. Proetel, Ulrike
   2. Pletsch, Nadine
   3. Lauseker, Michael
   4. Müller, Martin C
   5. Hanfstein, Benjamin
   6. Krause, Stefan W
   7. Kalmanti, Lida

   2014 - Forschungsinformationssystem des UKE
3. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

   1. Hehlmann, Rüdiger
   2. Lauseker, Michael
   3. Jung-Munkwitz, Susanne
   4. Leitner, Armin
   5. Müller, Martin C
   6. Pletsch, Nadine
   7. Proetel, Ulrike

   2011 - Forschungsinformationssystem des UKE